公开(公告)号：US11911474B2

公开(公告)日：2024-02-27

申请号：US17141753

申请日：2021-01-05

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Sayda M. Elbashir

IPC: A61K47/18 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/19 ,  A61K38/48 ,  A61K47/22 ,  A61K47/28 ,  C07K14/535 ,  C12N15/67 ,  C12N15/87 ,  C12N9/64 ,  A61K48/00

CPC classification number: A61K47/18 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/193 ,  A61K38/4846 ,  A61K47/22 ,  A61K47/28 ,  C07K14/535 ,  C12N9/644 ,  C12N15/67 ,  C12N15/87 ,  A61K48/00 ,  C12N2310/335

Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

公开(公告)号：US10703789B2

公开(公告)日：2020-07-07

申请号：US16438978

申请日：2019-06-12

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K48/00 ,  A61K38/17 ,  A61K47/54 ,  A61K9/127 ,  C07K14/535 ,  C12N15/88 ,  A61K9/50 ,  C07K14/47 ,  A61K31/7088 ,  C07K19/00 ,  C12N15/85 ,  A61K38/18 ,  A61K38/19 ,  A61K38/48 ,  A61K9/14 ,  A61K47/10 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K39/395 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/28 ,  C07K16/32 ,  C12N9/02 ,  C12N9/64 ,  A61K31/7115 ,  C07K14/005 ,  C12N15/11 ,  C12N9/00 ,  A61K9/00

Abstract: A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, N1-methyl-pseudouridine, a 3′-UTR, and a poly-A region with at least 100 nucleotides.

公开(公告)号：US20190185529A1

公开(公告)日：2019-06-20

申请号：US16036170

申请日：2018-07-16

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Tirtha Chakraborty ,  Joshua P. Frederick ,  Matthias John ,  Antonin De Fougerolles

IPC: C07K14/47 ,  A61K31/711 ,  C12N15/85 ,  C12N15/113 ,  A61K48/00 ,  A61K31/7105

CPC classification number: C07K14/47 ,  A61K31/7105 ,  A61K31/711 ,  A61K38/00 ,  A61K48/0058 ,  C12N15/113 ,  C12N15/85 ,  C12N2310/141

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of signal-sensor polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US10286086B2

公开(公告)日：2019-05-14

申请号：US15319840

申请日：2015-06-19

Applicant: ModernaTX, Inc.

Inventor： Atanu Roy ,  Christopher R. Conlee ,  Antonin De Fougerolles ,  Andrew W. Fraley ,  Gabor Butora ,  Matthew Stanton

IPC: A61K48/00 ,  C07F9/6558 ,  C07H19/06 ,  C07H19/16 ,  C12N15/11 ,  C12N15/67 ,  C07H21/02 ,  C07F9/6561 ,  C07D405/04 ,  C07D239/54 ,  C07H19/067 ,  C07H19/10 ,  C07H19/14 ,  C07H19/167 ,  C07H19/20 ,  C07H19/23 ,  C07D473/16 ,  C07D473/18 ,  C07D473/30 ,  C07D473/34 ,  C07D473/38 ,  C07D473/40 ,  C07D487/04 ,  C07D487/16 ,  C07D498/22 ,  C12N15/87

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.

公开(公告)号：US10772975B2

公开(公告)日：2020-09-15

申请号：US15790246

申请日：2017-10-23

Applicant: ModernaTX, Inc.

Inventor： Stephane Bancel ,  Tirtha Chakraborty ,  Antonin De Fougerolles ,  Sayda M. Elbashir ,  Matthias John ,  Atanu Roy ,  Susan Whoriskey ,  Kristy M. Wood ,  Paul Hatala ,  Jason P. Schrum ,  Kenechi Ejebe ,  Jeff Lynn Ellsworth ,  Justin Guild

IPC: C07K14/535 ,  A61K38/17 ,  A61K48/00 ,  C12N15/85 ,  C07K14/47 ,  C07K14/62 ,  A61K31/7115 ,  C12N9/88 ,  A61K9/127 ,  C12N15/11 ,  C07K14/705 ,  C07K14/505 ,  C12N9/64 ,  C12N9/10 ,  C12N9/00 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C07K14/005 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07H21/02 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K47/54 ,  A61K9/14 ,  A61K9/51 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/48 ,  C07K14/515 ,  C07K16/00 ,  A61K31/7088 ,  A61K47/10 ,  A61K38/00

Abstract: The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, a 3′-UTR, and a poly-A region with at least 100 nucleotides.

公开(公告)号：US10583203B2

公开(公告)日：2020-03-10

申请号：US16442168

申请日：2019-06-14

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K48/00 ,  A61K31/7115 ,  A61K38/17 ,  A61K47/54 ,  A61K9/127 ,  C07K14/005 ,  C12N15/11 ,  C12N9/00 ,  C12N15/85 ,  C07K14/62 ,  C07K14/47 ,  A61K38/19 ,  A61K38/18 ,  A61K9/51 ,  C12P21/00 ,  A61K9/14 ,  C07K16/00 ,  C07K14/515 ,  A61K38/48 ,  A61K38/21 ,  C12N9/64 ,  C07H21/02 ,  C07K14/435 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  C12P13/04 ,  C12N15/87 ,  A61K38/45 ,  C12N9/24 ,  C12N9/16 ,  C07K14/535 ,  C07K14/505 ,  C07K14/705 ,  C12N15/52 ,  C12N9/42 ,  C12N9/10 ,  C07K14/485 ,  C12N9/88 ,  A61K38/00

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US10463751B2

公开(公告)日：2019-11-05

申请号：US15425645

申请日：2017-02-06

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K48/00 ,  A61K31/7115 ,  A61K38/17 ,  A61K47/54 ,  A61K9/127 ,  C07K14/005 ,  C12N15/11 ,  C12N9/00 ,  C12N15/85 ,  C07K14/47 ,  C07K14/62 ,  C12N9/88 ,  C07K14/705 ,  C07K14/505 ,  C07K14/535 ,  C12N9/64 ,  C12N9/10 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07H21/02 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K9/14 ,  A61K9/51 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/48 ,  C07K14/515 ,  C07K16/00 ,  A61K38/00

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US10385106B2

公开(公告)日：2019-08-20

申请号：US14987328

申请日：2016-01-04

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K47/10 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/48 ,  A61K9/14 ,  C07K14/535 ,  A61K48/00 ,  A61K47/54 ,  C12N15/88 ,  A61K9/127 ,  A61K9/50 ,  A61K31/7088 ,  C07K19/00 ,  C12N15/85 ,  C07K14/47 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K39/395 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/28 ,  C07K16/32 ,  C12N9/02 ,  C12N9/64 ,  A61K9/00

Abstract: The present disclosure describes compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 5-methoxy-uridines to improve the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, protein half-life and/or modulation of a cell's status function, and/or activity.

公开(公告)号：US20170130255A1

公开(公告)日：2017-05-11

申请号：US15356132

申请日：2016-11-18

Applicant: ModernaTX, Inc.

Inventor： Yuxun Wang ,  Divakar Ramakrishnan ,  Antonin De Fougerolles ,  Susan Whoriskey

IPC: C12P19/34 ,  C12N9/12

CPC classification number: C12P19/34 ,  C12N9/1241 ,  C12N9/1247 ,  C12N9/1252 ,  C12Y207/07006 ,  C12Y207/07007 ,  C12Y207/0705

Abstract: The invention relates to compositions and methods for the design, evolution, preparation, and/or manufacture of enzymes for use with polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US12023371B2

公开(公告)日：2024-07-02

申请号：US17127435

申请日：2020-12-18

Applicant: ModernaTX, Inc.

Inventor： Tirtha Chakraborty ,  Stephane Bancel ,  Stephen G. Hoge ,  Atanu Roy ,  Antonin De Fougerolles ,  Noubar B. Afeyan

IPC: A61K39/00 ,  C12N15/67

CPC classification number: A61K39/00 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.